FDA's Pe­ter Marks over­rode re­view­ers’ call to re­ject Sarep­ta’s new Duchenne gene ther­a­py

Pe­ter Marks, the se­nior FDA of­fi­cial who over­sees the reg­u­la­tion of gene ther­a­pies, over­rode agency re­view­ers’ de­ci­sion to re­ject Sarep­ta Ther­a­peu­tics’ Duchenne mus­cu­lar dy­s­tro­phy gene …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER